Skip to main content
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

More stories below advertisement

KP Tissue Releases Second Quarter 2020 Financial Results

GlobeNewswire - Thu Aug 6, 6:00AM CDT

KP Tissue Inc. (KPT) (TSX:KPT.TO) reports the Q2 2020 financial and operational results of KPT and Kruger Products L.P. (KPLP). Kruger Products is Canada's leading manufacturer of quality tissue products for the Consumer market (Cashmere, Purex, SpongeTowels, Scotties, and White Swan) and the Away-From-Home market, and continues to grow in the U.S. Consumer tissue business with the White Cloud(R) brand and premium private label products. KPT currently holds a 14.8% interest in KPLP.

KPLP Q2 2020 Business and Financial Highlights

-- Revenue increased by $21.1 million or 5.8% to $386.8 million in Q2 2020 compared to $365.7 million in Q2 2019. Excluding the divested Mexico business, Q2 2020 revenue increased by $46.5 million or 13.7%.

-- Adjusted EBITDA was $64.4 million in Q2 2020 compared to $31.5 million in Q2 2019, an increase of 104.6%.

-- TAD Sherbrooke site progressing on time and on budget despite the temporary shutdown in Q1 2020 due to the implementation of strict COVID-19 protocols.

-- Declared a quarterly dividend of $0.18 per share to be paid on October 15, 2020.

"Our robust second quarter results were driven by a consistent increased demand in our Consumer segment and strong operational performance. We continued to benefit from the trust in our brands, leading to market share gains that began at the end of last year. We also gained new listings and new customers, and saw good growth and increased distribution in our U.S. White Cloud brand. As expected, the Away-from-Home segment faced challenging market conditions during the quarter and the road to recovery in this market will depend on the evolving COVID-19 situation," stated KP Tissue Chief Executive Officer, Dino Bianco.

"Adjusted EBITDA performance was exceptional with growth of over 100% to $64.4 million. The increase reflects higher Consumer volume and a favourable cost environment as well as the sustainable benefits of our OpEx program across all operations.

"Despite a temporary halt to construction as we implemented COVID-19 procedures, we are pleased to report that TAD Sherbrooke remains on time and on budget. As planned, the first converting-line started in July and the ramp-up is progressing well. With paper production expected to begin in early 2021, the new facility is central to our long-term North American growth strategy in the ultra-premium tissue segment. Furthermore, we have a fully committed sales pipeline in support of our largest investment in Kruger Products' history.

"In addition to robust quarterly performance, we continue to reinvest in our brands and business in order to build an even stronger future. Lastly, I would like to thank the entire Kruger Products team for working safe while driving strong performance during COVID-19," concluded Mr. Bianco.

Outlook

Demand for our products is expected to remain strong but at a diminishing growth rate in the Consumer segment and weaker in the Away-From-Home segment, with input costs expected to remain unchanged. As COVID-19 continues to evolve, there are many opportunities and uncertainties in the market. Given this, we are providing a wide range for Q3 2020 Adjusted EBITDA that is above Q3 2019 and below Q2 2020.

KPLP Q2 2020 Financial Results

Revenue was $386.8 million in Q2 2020 compared to $365.7 million in Q2 2019, an increase of $21.1 million or 5.8%. The increase in revenue was primarily due to significant volume increases in the Consumer business segment, resulting primarily from COVID-19 buying activity and the favourable impact of foreign exchange fluctuations, partially offset by lower volume in the AFH business segment resulting from the ongoing impacts from COVID-19, Consumer selling prices moderating lower in response to lower pulp prices, and no volume from Mexico as a result of the share sale at the end of Q3 2019. Mexico revenue was $25.4 million in Q2 2019. Excluding the Mexico business, revenue increased by $46.5 million or 13.7%

Cost of sales was $310.0 million in Q2 2020 compared to $325.8 million in Q2 2019, a decrease of $15.8 million or 4.8%. Manufacturing costs decreased primarily due to favourable pulp costs, the impact of operational transformation initiatives (OpEx) and the COVID-19 reduced sku production environment. The decreases were partially offset by the unfavourable impact of foreign exchange fluctuations, inflation and additional costs due to precautions taken in our manufacturing facilities as a result of COVID-19. Freight costs decreased compared to Q2 2019 while warehousing costs increased. As a percentage of revenue, cost of sales was 80.2% in Q2 2020 compared to 89.1% in Q2 2019.

Selling, general and administrative (SG&A) expenses were $30.5 million in Q2 2020 compared to $25.4 million in Q2 2019, an increase of $5.1 million or 20.2%. The increase was primarily due to higher compensation and personnel related costs compared to Q2 2019 and higher selling expenses due to increased volume. As a percentage of revenue, SG&A expenses were 7.9% in Q2 2020 compared to 6.9% in Q2 2019.

Adjusted EBITDA was $64.4 million in Q2 2020 compared to $31.5 million in Q2 2019, an increase of $32.9 million or 104.6%. The increase was primarily due to higher sales volume, the favourable impact of lower pulp prices and lower manufacturing costs compared to Q2 2019 as described above and favourable freight costs. The increases were partially offset by higher maintenance, warehousing and SG&A costs.

Net income was $28.9 million in Q2 2020 compared to $0.9 million in Q2 2019, an increase of $28.0 million. The increase was primarily due to higher Adjusted EBITDA of $32.9 million as discussed, partially offset by higher income tax expense and an increase in depreciation expense.

KPLP Q2 2020 Financing Activity

Total liquidity, representing cash and availability under the Senior Credit Facility within covenant limitations, was $271.7 million as of June 30, 2020. In addition, $37.8 million of cash was held by KPSI and committed to the TAD Sherbrooke Project.

KPT Q2 2020 Financial Results

KPT had a net loss of $0.1 million in Q2 2020. Included in net loss was $4.3 million representing KPT's share of KPLP's net income, depreciation expense of $1.4 million related to adjustments to carrying amounts on acquisition and income tax expense of $3.3 million.

Dividends on Common Shares

The Board of Directors of KPT declared a quarterly dividend of $0.18 per share to be paid on October 15, 2020 to shareholders of record at the close of business on September 30, 2020.

Additional Information

For additional information please refer to Management's Discussion and Analysis (MD&A) of KPT and KPLP for the second quarter ended June 30, 2020 available on SEDAR at www.sedar.com or our website at www.kptissueinc.com.

Second Quarter Results Conference Call Information

KPT will hold its second quarter conference call on Thursday, August 6, 2020 at 8:30 a.m. Eastern Time.

Via telephone: 1-877-223-4471 or 647-788-4922

Via the internet at: www.kptissueinc.com

Presentation material referenced during the conference call will be available at www.kptissueinc.com.

A rebroadcast of the conference call will be available until midnight, August 13, 2020 by dialing 1-800-585-8367 or 416-621-4642 and entering passcode 1935229.

The replay of the webcast will remain available on the website until midnight, August 13, 2020.

About KP Tissue Inc. (KPT)

KPT was created to acquire, and its business is limited to holding, a limited partnership interest in KPLP, which is accounted for as an investment on the equity basis. KPT currently holds a 14.8% interest in KPLP. For more information visit www.kptissueinc.com.

About Kruger Products L.P. (KPLP)

KPLP is Canada's leading manufacturer of quality tissue products for household, industrial and commercial use. KPLP serves the Canadian consumer market with such well-known brands as Cashmere(R), Purex(R), SpongeTowels(R), Scotties(R) and White Swan(R). In the U.S., KPLP manufactures the White Cloud(R) brand, as well as many private label products. The Away-From-Home division manufactures and distributes high-quality, cost-effective product solutions to a wide range of commercial and public entities. KPLP has approximately 2,500 employees and operates eight FSC(R) COC-certified (FSC(R) C-104904) production facilities in North America. For more information visit www.krugerproducts.ca.

Non-IFRS Measures

This press release uses certain non-IFRS financial measures which KPLP believes provide useful information to management of KPLP and the readers of the financial information in measuring the financial performance and financial condition of KPLP. These measures do not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similarly titled measures presented by other companies. An example of such a measure is Adjusted EBITDA. Beginning with Q4 2015 in accordance with Canadian Securities Administrators Staff Notice 52-306 (Revised), we have referenced Adjusted EBITDA as a non-IFRS financial measure. This term replaces the previously referenced non-IFRS financial measure EBITDA. Adjusted EBITDA is not a measurement of operating performance computed in accordance with IFRS and should not be considered as a substitute for operating income, net income or cash flows from operating activities computed in accordance with IFRS. "Adjusted EBITDA" is calculated by KPLP as net income (loss) before (i) interest expense, (ii) income taxes, (iii) depreciation, (iv) amortization, (v) impairment (gain on sale) of non-financial assets, (vi) loss (gain) on disposal of property, plant and equipment, (vii) foreign exchange loss (gain), (viii) costs related to restructuring activities, (ix) changes in amortized cost of Partnership units liability, (x) change in fair value of derivatives, (xi) consulting costs related to operational transformation initiatives, (xii) corporate development related costs and (xiii) loss (gain) on sale of shares. A reconciliation of Adjusted EBITDA to the relevant reported results can be found in the MD&A of KPT and KPLP for the year ended December 31, 2019 available on SEDAR at www.sedar.com.

COVID-19

In March 2020, the World Health Organization characterized the outbreak of the novel strain of coronavirus, specifically identified as "COVID-19", as a global pandemic. This has resulted in local governments enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and social distancing, have caused material disruption to businesses in the United States of America and Canada resulting in an economic slowdown. Equity markets have experienced significant volatility and weakness and the local governments and central banks have reacted with significant monetary and fiscal interventions designed to stabilize economic conditions. There is significant uncertainty as to the likely effects of this outbreak. The duration and impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank interventions. It is not possible to reliably estimate the length and severity of these developments to quantify the impact this pandemic may have on the financial results and condition of KPLP in future periods.

Forward-Looking Statements

Certain statements in this press release about KPT's and KPLP's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements or any other future events or developments constitute forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding the projected capacity of the TAD Sherbrooke Project, the anticipated benefits of the TAD Sherbrooke Project and the expected dates for commencement of construction and production of the TAD Sherbrooke Project. The words "may", "will", "would", "should", "could", "expects", "plans", "intends", "trends", "indications", "anticipates", "believes", "estimates", "predicts", "likely" or "potential" or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. The forward-looking statements are based on certain key expectations and assumptions made by KPT or KPLP. Although KPT and KPLP believe that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking statements since no assurance can be given that such expectations and assumptions will prove to be correct.

The outlook provided in respect of Adjusted EBITDA for Q3 2020 is forward-looking information and is subject to the risk and uncertainties referred to below. The purpose of the outlook is to provide the reader with an indication of management's expectations, at the date of this press release, regarding KPLP's future financial performance. Readers are cautioned that this information may not be appropriate for other purposes.

Many factors could cause KPLP's actual results, level of activity, performance or achievements or future events or developments (which could in turn affect the economic benefits derived from KPT's economic interest in KPLP), to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the following factors, which are discussed in greater detail in the "Risk Factors - Risks Related to KPLP's Business" section of the KPT Annual Information Form dated March 30, 2020 available on SEDAR at www.sedar.com: Kruger Inc.'s influence over KPLP; KPLP's reliance on Kruger Inc.; consequences of an event of insolvency relating to Kruger Inc.; risks associated with the TAD Sherbrooke Project; operational risks; significant increases in input costs; reduction in supply of fibre; increased pricing pressure and intense competition; KPLP's inability to innovate effectively; adverse economic conditions; dependence on key retail trade customers; damage to the reputation of KPLP or KPLP's brands; KPLP's sales being less than anticipated; KPLP's failure to implement its business and operating strategies; KPLP's obligation to make regular capital expenditures; KPLP's entering into unsuccessful acquisitions; KPLP's dependence on key personnel; KPLP's inability to retain its existing customers or obtain new customers; KPLP's loss of key suppliers; KPLP's failure to adequately protect its intellectual property rights; KPLP's reliance on third party intellectual property licenses; adverse litigation and other claims affecting KPLP; material expenditures due to comprehensive environmental regulation affecting KPLP's cash flow; KPLP's pension obligations are significant and can be materially higher than predicted if KPLP Management's underlying assumptions are incorrect; labour disputes adversely affecting KPLP's cost structure and KPLP's ability to run its plants; exchange rate and U.S. competitors; KPLP's inability to service all of its indebtedness; exposure to potential consumer product liability; covenant compliance; interest rate and refinancing risk; risks relating to information technology; cyber-security; insurance; internal controls; trade; and risks related to COVID-19.

Readers should not place undue reliance on forward-looking statements made herein. The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. The forward-looking information contained herein is made as of the date of press release and KPT undertakes no obligation to publicly update such forward-looking information to reflect new information, subsequent or otherwise, unless required by applicable securities laws.

INFORMATION:

Francois Paroyan

General Counsel and Corporate Secretary

KP Tissue Inc.

Tel.: 905.812.6936

francois.paroyan@krugerproducts.ca

INVESTORS:

Mike Baldesarra

Director of Investor Relations

KP Tissue Inc.

Tel.: 905.812.6962

IR@KPTissueinc.com

Kruger Products L.P.
Unaudited Condensed Consolidated Statement of Financial Position
(thousands of Canadian dollars)
                                                                June 30, 2020    December 31, 2019
                                                                $                $
Assets
Current assets
               Cash and cash equivalents                        144,188          93,141
               Trade and other receivables                      89,431           89,236
               Receivables from related parties                 16               59
               Current portion of advances to partners          2,323            80
               Inventories                                      193,214          190,686
               Income tax recoverable                           -                466
               Prepaid expenses                                 15,273           8,341
                                                                444,445          382,009
Non-current assets
               Property, plant and equipment                    1,063,825        935,010
               Right-of-use assets                              92,402           97,582
               Other long-term assets                           10               1,766
               Goodwill                                         160,939          160,939
               Intangible assets                                16,137           15,317
               Deferred income taxes                            24,750           30,988
Total assets                                                    1,802,508        1,623,611
Liabilities
Current liabilities
               Trade and other payables                         254,773          242,357
               Payables to related parties                      10,178           6,809
               Income tax payable                               1,242            325
               Distributions payable                            11,760           11,393
               Current portion of provisions                    3,509            759
               Current portion of long-term debt                4,937            11,937
               Current portion of lease liabilities             19,796           18,080
                                                                306,195          291,660
Non-current liabilities
               Long-term debt                                   700,388          579,125
               Lease liabilities                                93,987           100,682
               Provisions                                       5,196            6,148
               Pensions                                         179,153          140,674
               Post-retirement benefits                         61,021           57,005
               Liabilities to non-unitholders                   1,345,940        1,175,294
               Current portion of Partnership units liability   12,599           5,103
               Long-term portion of Partnership units liability 130,853          138,412
               Total Partnership units liability                143,452          143,515
Total liabilities                                               1,489,392        1,318,809
Equity
               Partnership units                                428,936          408,978
               Deficit                                          (209,059      )  (183,188          )
               Accumulated other comprehensive income           93,239           79,012
Total equity                                                    313,116          304,802
Total equity and liabilities                                    1,802,508        1,623,611
Kruger Products L.P.
Unaudited Condensed Consolidated Statement of Comprehensive Income (Loss)
(thousands of Canadian dollars)
                                                                  3-month          3-month          6-month          6-month
                                                                  period ended     period ended     period ended     period ended
                                                                  June 30, 2020    June 30, 2019    June 30, 2020    June 30, 2019
                                                                  $                $                $                $
Revenue                                                           386,763          365,674          761,909          716,651
Expenses
Cost of sales                                                     310,009          325,723          624,522          645,831
Selling, general and administrative expenses                      30,492           25,370           60,126           47,426
Loss on sale of non-financial assets                              -                6                1                6
Restructuring costs, net                                          483              232              1,221            297
Operating income                                                  45,779           14,343           76,039           23,091
Interest expense                                                  11,333           11,433           21,913           22,730
Other (income) expense                                            (3,269        )  864              8,152            1,713
Income (loss) before income taxes                                 37,715           2,046            45,974           (1,352        )
Income taxes                                                      8,811            1,114            8,682            928
Net income (loss) for the period                                  28,904           932              37,292           (2,280        )
Other comprehensive income (loss)
Items that will not be reclassified to net income (loss):
Remeasurements of pensions                                        (103,032      )  (52,439       )  (36,655       )  (50,412       )
Remeasurements of post-retirement benefits                        (9,896        )  (4,201        )  (3,388        )  (6,331        )
Items that may be subsequently reclassified to net income (loss):
Cumulative translation adjustment                                 (12,480       )  (6,123        )  14,227           (12,513       )
Total other comprehensive loss for the period                     (125,408      )  (62,763       )  (25,816       )  (69,256       )
Comprehensive income (loss) for the period                        (96,504       )  (61,831       )  11,476           (71,536       )
Kruger Products L.P.
Unaudited Condensed Consolidated Statement of Cash Flows
(thousands of Canadian dollars)
                                                                                 3-month             3-month             6-month             6-month
                                                                                 period ended        period ended        period ended        period ended
                                                                                 June 30, 2020       June 30, 2019       June 30, 2020       June 30, 2019
                                                                                 $                   $                   $                   $
Cash flows from (used in) operating activities
Net income (loss) for the period                                                 28,904              932                 37,292              (2,280        )
Items not affecting cash
Depreciation                                                                     16,515              14,516              32,960              28,896
Amortization                                                                     399                 370                 773                 732
(Gain) loss on sale of property, plant and equipment                             49                  -                   49                  (5            )
Change in amortized cost of Partnership units liability                          2,520               1,547               5,040               3,094
Foreign exchange (gain) loss                                                     (5,789        )     (960          )     3,472               (1,658        )
Change in fair value of derivatives                                              -                   277                 (360          )     277
Interest expense                                                                 11,333              11,433              21,913              22,730
Pension and post-retirement benefits                                             3,694               2,756               7,474               5,201
Provisions                                                                       1,844               503                 3,599               673
Income taxes                                                                     8,811               1,114               8,682               928
Loss on sale of non-financial assets                                             -                   6                   1                   6
Total items not affecting cash                                                   39,376              31,562              83,603              60,874
Net change in non-cash working capital                                           47,540              7,819               26,035              (44,806       )
Contributions to pension and post-retirement benefit plans                       (3,853        )     (4,041        )     (7,938        )     (7,153        )
Provisions paid                                                                  (1,663        )     (407          )     (1,871        )     (472          )
Income tax payments                                                              (13           )     (1,338        )     (13           )     (1,597        )
Net cash from operating activities                                               110,291             34,527              137,108             4,566
Cash flows from (used in) investing activities
Purchases of property, plant and equipment                                       (3,405        )     (6,759        )     (7,451        )     (12,280       )
Purchases of property, plant and equipment related to the TAD Sherbrooke Project (67,320       )     (31,092       )     (132,013      )     (42,208       )
Interest paid on credit facilities related to the TAD Sherbrooke Project         (2,054        )     (769          )     (4,204        )     (1,453        )
Purchases of software                                                            (548          )     (116          )     (1,593        )     (1,334        )
Proceeds on sale of shares                                                       -                   -                   992                 -
Proceeds on sale of property, plant and equipment                                -                   -                   -                   5
Net cash used in investing activities                                            (73,327       )     (38,736       )     (144,269      )     (57,270       )
Cash flows from (used in) financing activities
Proceeds from long-term debt                                                     26,754              10,411              132,327             35,188
Repayment of long-term debt                                                      (32,434       )     (6,032        )     (33,701       )     (7,286        )
Payment of deferred financing fees                                               (488          )     (67           )     (493          )     (353          )
Payment of lease liabilities                                                     (5,426        )     (4,041        )     (9,917        )     (8,266        )
Interest paid on long-term debt                                                  (19,702       )     (11,359       )     (21,622       )     (13,947       )
Distributions and advances paid, net                                             (3,724        )     (3,574        )     (10,221       )     (5,544        )
Net cash from (used in) financing activities                                     (35,020       )     (14,662       )     56,373              (208          )
Effect of exchange rate changes on cash and cash
equivalents held in foreign currency                                             (2,395        )     (699          )     1,835               (1,537        )
Increase (decrease) in cash and cash equivalents during the period               (451          )     (19,570       )     51,047              (54,449       )
Cash and cash equivalents - Beginning of period                                  144,639             135,005             93,141              169,884
Cash and cash equivalents - End of period                                        144,188             115,435             144,188             115,435
Kruger Products L.P.
Segment and Geographic Results
(thousands of Canadian dollars)
                                                        3-month       3-month       6-month       6-month
                                                        period ended  period ended  period ended  period ended
                                                        June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019
                                                        $             $             $             $
Segment Information
Segment Revenue
Consumer                                                338,242       299,663       651,531       595,848
AFH                                                     48,521        66,011        110,378       120,803
Total segment revenue                                   386,763       365,674       761,909       716,651
Adjusted EBITDA
Consumer                                                69,580        35,354        123,929       65,446
AFH                                                     (2,145  )     (3,045  )     (3,166  )     (9,629  )
Corporate and other costs                               (3,012  )     (820    )     (5,389  )     (778    )
Total Adjusted EBITDA                                   64,423        31,489        115,374       55,039
Reconciliation to Net Income (Loss):
Depreciation and amortization                           16,914        14,886        33,733        29,628
Interest expense                                        11,333        11,433        21,913        22,730
Change in amortized cost of Partnership units liability 2,520         1,547         5,040         3,094
Change in fair value of derivatives                     -             277           (360    )     277
(Gain) loss on sale of property, plant and equipment    49            -             49            (5      )
Loss on sale of non-financial assets                    -             6             1             6
Restructuring costs, net                                483           232           1,221         297
Foreign exchange (gain) loss                            (5,789  )     (960    )     3,472         (1,658  )
Consulting costs
related to operational transformation initiatives       1,198         1,283         4,331         1,283
Corporate development related costs                     -             739           -             739
Income (loss) before income taxes                       37,715        2,046         45,974        (1,352  )
Income taxes                                            8,811         1,114         8,682         928
Net income (loss)                                       28,904        932           37,292        (2,280  )
Geographic Revenue
Canada                                                  218,438       208,163       448,533       405,579
US                                                      168,325       132,063       313,376       259,576
Mexico                                                  -             25,448        -             51,496
Total revenue                                           386,763       365,674       761,909       716,651
KP Tissue Inc.
Unaudited Condensed Statement of Financial Position
(thousands of Canadian dollars)
                                             June 30, 2020    December 31, 2019
                                             $                $
Assets
Current assets
Distributions receivable                     1,745            1,733
Receivable from Partnership                  73               247
                                             1,818            1,980
Non-current assets
Investment in associate                      77,176           81,052
Total Assets                                 78,994           83,032
Liabilities
Current liabilities
Dividend payable                             1,745            1,733
Current portion of advances from Partnership 360              80
Income tax payable                           1,281            944
                                             3,386            2,757
Non-current liabilities
Deferred income taxes                        1,551            3,158
Total liabilities                            4,937            5,915
Equity
Common shares                                19,669           18,997
Contributed surplus                          144,819          144,819
Deficit                                      (106,559      )  (100,696          )
Accumulated other comprehensive income       16,128           13,997
Total equity                                 74,057           77,117
Total liabilities and equity                 78,994           83,032
KP Tissue Inc.
Unaudited Condensed Statement of Comprehensive Loss
(thousands of Canadian dollars, except share and per share amounts)
                                                                  3-month          3-month          6-month          6-month
                                                                  period ended     period ended     period ended     period ended
                                                                  June 30, 2020    June 30, 2019    June 30, 2020    June 30, 2019
                                                                  $                $                $                $
Equity income (loss)                                              2,925            (1,288        )  2,800            (3,237        )
Dilution gain                                                     231              142              451              231
Income (loss) before income taxes                                 3,156            (1,146        )  3,251            (3,006        )
Income taxes                                                      3,279            1,437            1,673            1,529
Net income (loss) for the period                                  (123          )  (2,583        )  1,578            (4,535        )
Other comprehensive income (loss)
net of tax expense (recovery)
Items that will not be reclassified to net income (loss):
Remeasurements of pensions                                        (12,347       )  (6,827        )  (3,655        )  (6,550        )
Remeasurements of post-retirement benefits                        (906          )  (390          )  (309          )  (586          )
Items that may be subsequently reclassified to net income (loss):
Cumulative translation adjustment                                 (1,950        )  (1,012        )  2,131            (2,112        )
Total other comprehensive loss for the period                     (15,203       )  (8,229        )  (1,833        )  (9,248        )
Comprehensive loss for the period                                 (15,326       )  (10,812       )  (255          )  (13,783       )
Basic earnings (loss) per share                                   (0.01         )  (0.27         )  0.16             (0.48         )
Weighted average number of shares outstanding                     9,689,578        9,515,910        9,672,481        9,490,276
KP Tissue Inc.
Unaudited Condensed Statement of Cash Flows
(thousands of Canadian dollars)
                                                                   3-month            3-month            6-month            6-month
                                                                   period ended       period ended       period ended       period ended
                                                                   June 30, 2020      June 30, 2019      June 30, 2020      June 30, 2019
                                                                   $                  $                  $                  $
Cash flows from (used in) operating activities
Net income (loss) for the period                                   (123          )    (2,583        )    1,578              (4,535        )
Items not affecting cash
Equity (income) loss                                               (2,925        )    1,288              (2,800        )    3,237
Dilution gain                                                      (231          )    (142          )    (451          )    (231          )
Income taxes                                                       3,279              1,437              1,673              1,529
Total items not affecting cash                                     123                2,583              (1,578        )    4,535
Net change in non-cash working capital                             1                  -                  94                 -
Tax payments                                                       (361          )    -                  (1,235        )    -
Tax Distribution                                                   -                  -                  781                -
Advances received                                                  360                -                  360                -
Net cash from (used in) operating activities                       -                  -                  -                  -
Cash flows from investing activites
Partnership unit distributions received                            1,400              1,279              2,793              2,427
Net cash from investing activities                                 1,400              1,279              2,793              2,427
Cash flows used in financing activities
Dividends paid                                                     (1,400        )    (1,279        )    (2,793        )    (2,427        )
Net cash used in financing activities                              (1,400        )    (1,279        )    (2,793        )    (2,427        )
Increase (decrease) in cash and cash equivalents during the period -                  -                  -                  -
Cash and cash equivalents - Beginning of period                    -                  -                  -                  -
Cash and cash equivalents - End of period                          -                  -                  -                  -

https://ml.globenewswire.com/media/cc666126-8ad7-4166-a7af-440392e81526/small/kp-tissue-inc-jpg.jpg

comtex tracking

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies